ADSAT Therapeutics
Treating Autoimmune Disease
ADSAT Therapeutics
Treating Autoimmune Disease
About Us
Our Science
ADSAT Therapeutics is developing a novel immunomodulatory molecule demonstrated to reverse Type 1 Diabetes in the NOD mouse model
Toleromab
Our lead molecule is called Toleromab and is an immunoglobulin-based protein that induces tolerance in Type 1 Diabetes
Our Advantage
Toleromab is designed to be a specific suppressant of autoreactive T-cells leading to regeneration of islet function and insulin independence
OUr Status
Humanization of Toleromab
We are a preclinical stage biopharmaceutical company. Our near-term objectives are to humanize the Toleromab molecule and test it in mice that have an established human immune system.
Preclinical Development
Successful demonstration of Toleromab efficacy in the humanized mouse model will lead to standard preclinical development for first-in-man studies
Platform Enhancement
We are pursuing additional products that complement or augment the mode of action of Toleromab to bring this important treatment to additional patients
OUR Founders
Habib Zaghouani, Ph.D. Chief Scientific Officer
Habib Zaghouani, Ph.D. Chief Scientific Officer
Habib Zaghouani, Ph.D. Chief Scientific Officer
University of Missouri
Professor, Neurology, Immunology and Molecular Microbiology
Inventor of technology
5 patents issued
$5M of NIH Funding
Paul Hippenmeyer, Ph.D., MBA CEO
Habib Zaghouani, Ph.D. Chief Scientific Officer
Habib Zaghouani, Ph.D. Chief Scientific Officer
Monsanto/Searle/Pharmacia Science Fellow
Director of Research-Keel Pharmaceuticals
Licensing/Business Development
University of Missouri
Washington University.
Contact Us
Copyright © 2023 ADSAT Therapeutics - All Rights Reserved.
Powered by GoDaddy
This website uses cookies.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.